Literature DB >> 2483423

A review of the renin-angiotensin system in the normal heart.

A Mebazaa1, B Chevalier, J J Mercadier, E Echter, L Rappaport, B Swynghedauw.   

Abstract

This review describes the vascular and cardiac tissue renin-angiotensin system (RAS), a so-called autocrine hormonal system as opposed to the circulating endocrine system. The existence of this autocrine system is suggested by the persistence of elevated concentrations of angiotensin II (Ang II) following binephrectomy. There is considerable evidence to support the concept of an autocrine RAS, but the functional aspects of such a system remain controversial: (a) Cultured endothelial cells from blood vessels can, for example, synthesize renin, but angiotensinogen messenger RNA (mRNA) is only present in perivascular adipocytes. (b) In the myocardium, there are obviously problems raised depending on the animal species considered: only rats apparently lack ventricular RAS, but tissue RAS is present in their atrial and conducting tissue system. In other species such as rabbit, the situation is quite different. In addition to the inotropic effect of Ang II, it has recently been demonstrated that this substance may determine the expression of the cardiac genome (oncogenes).

Entities:  

Mesh:

Year:  1989        PMID: 2483423

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

1.  Angiotensin II-forming heart chymase is a mast-cell-specific enzyme.

Authors:  D E Jenne; J Tschopp
Journal:  Biochem J       Date:  1991-06-01       Impact factor: 3.857

Review 2.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

3.  Left ventricular diastolic function during adrenergic stress in essential hypertension: acute and chronic effects of ACE inhibition.

Authors:  G Covi; I Sheiban; G Gelmini; G Arcaro; S Tonni; A Bolner; G Piemonte; A Lechi
Journal:  Cardiovasc Drugs Ther       Date:  1996-07       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.